UBS has recently initiated Myriad Genetics Inc (MYGN) stock to Neutral rating, as announced on December 10, 2024, according to Finviz. Earlier, on December 9, 2024, Leerink Partners had reduced the ...
Triple negative breast cancer wreaks a particularly heavy toll in certain regions and populations, with stark differences in both incidence and survival rates ...